PCSK9: the new lipid target in preventive cardiology?
June 23, 2013Presentations & webcasts of this symposium will be posted soon
EBAC ACCREDITED EDUCATIONAL PROGRAMME HELD DURING THE ESC CONGRESS 2013
Saturday, August 31, 2013
14:45 – 15:45 hrs
Session 258, Ljubljana – Village 8
14:45 – 14:55: Introduction, Familial Hypercholesterolemia: Why are we not reaching goals in these patients?
- John Kastelein, Academic Medical Center, Amsterdam, Netherlands
14:55 – 15:10: PCSK9 inhibition: Mechanistic insights into a new therapeutic approach for the lowering of LDL-c
- Gilles Lambert, University of Nantes Medical School, Nantes, France
15:10 – 15:25: Monoclonal antibodies that target PCSK9: What the first clinical trial data are telling?
- Evan Stein, Metabolic and Atherosclerosis Research Center, Cincinnati, USA
15:25 – 15:40:The roadmap of PCSK9 inhibitors towards the clinic: An overview of current development programs & outcome studies
- Henry Ginsberg, Columbia University Medical Center, New York
15:40 – 15:45: Discussion & summary
- John Kastelein, Evan Stein
Organized and supervized by University College London, Course director; Prof John Deanfield
1 hour of external CME credit(s). Each participant should claim only those hours of credit that have
actually been spent in the educational activity.
EBAC works according to the quality standards the European Accreditation for Continuing Medical
Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
To secure a seat at the symposium please pre-register via this link
“In compliance with EBAC/ EACCME guidelines, all speakers/Chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.
The Organising Committee/ Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.”
EBAC ACCREDITED EDUCATIONAL PROGRAMME HELD DURING THE ESC CONGRESS 2013
Saturday, August 31, 2013
14:45 – 15:45 hrs
Session 258, Ljubljana – Village 8
Educational objectives
- Understand the unmet need for additional LDL-C-lowering therapies beyond current optimal statin-based therapy as a strategy for addressing lipid-related CV risk in patients with FH
- Understand the mechanisms and potential applications of emerging therapies to lower LDL through novel approaches that can be used in combination with statin therapy
- Describe the potential impact of PCSK9-based therapies in development in patients who require additional LDL-C reduction
- Compare and evaluate evidence from recent clinical trials of novel agents in clinical development and assess their impact on lipids and cardiovascular risk
Agenda
14:45 – 14:55: Introduction, Familial Hypercholesterolemia: Why are we not reaching goals in these patients?
- John Kastelein, Academic Medical Center, Amsterdam, Netherlands
14:55 – 15:10: PCSK9 inhibition: Mechanistic insights into a new therapeutic approach for the lowering of LDL-c
- Gilles Lambert, University of Nantes Medical School, Nantes, France
15:10 – 15:25: Monoclonal antibodies that target PCSK9: What the first clinical trial data are telling?
- Evan Stein, Metabolic and Atherosclerosis Research Center, Cincinnati, USA
15:25 – 15:40:The roadmap of PCSK9 inhibitors towards the clinic: An overview of current development programs & outcome studies
- Henry Ginsberg, Columbia University Medical Center, New York
15:40 – 15:45: Discussion & summary
- John Kastelein, Evan Stein
Organized and supervized by University College London, Course director; Prof John Deanfield
CME Accreditation
This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for1 hour of external CME credit(s). Each participant should claim only those hours of credit that have
actually been spent in the educational activity.
EBAC works according to the quality standards the European Accreditation for Continuing Medical
Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
Registration
Acces to this symposium is only for delegates registered for the ESC 2013 congressTo secure a seat at the symposium please pre-register via this link
Funding
Supported by an unrestricted educational grant from Amgen, Eli Lilly, Regeneron/Sanofi.“In compliance with EBAC/ EACCME guidelines, all speakers/Chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.
The Organising Committee/ Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.”